Today a new vaccine against malaria, largely developed in Nijmegen, is being tested for the first time in volunteers at Radboudumc.
Almost half a million people die of malaria every year, especially young children in Africa. The germs of malaria (the parasites) are transferred from one person to another via the malaria mosquito. This new vaccine aims to prevent this transmission, so malaria cannot spread further.
Scientists from Nijmegen were at the forefront of this vaccine in the 1990s, when they discovered a protein of the parasite (the Pfs48 / 45 protein) that plays an essential role in the transmission of the malaria parasite to the mosquito. By switching off this protein, the formation of new parasites in the mosquito can be blocked. This prevents other people from being infected via a mosquito bite. The vaccine doesn’t prevent you from getting malaria yourself, but it prevents the spread of malaria in other people. This was a completely new concept at the time. Together with Danish colleagues from the Statens Serum Institute, this protein has now been developed into a form (called R0.6C) that can be administered as a vaccine against malaria.
The so-called R0.6C vaccine is a recombinant product that targets the Pfs48 / 45 protein. This vaccine must generate antibodies (antibodies) against this protein in humans. If someone with malaria and the administered vaccine is bitten by a mosquito, that mosquito will also ingest the antibodies. Those antibodies will block the development of the parasites in the mosquito. This prevents further spread of malaria in the human population.
Whether the concept works must be carefully tested of course. The first test (phase 1 study), which is now being carried out on volunteers at Radboudumc, is investigating the safety of this vaccine. It’s also being examined whether antibodies that can prevent the transmission of malaria are indeed formed in the blood of the volunteers.
More at www.radboudumc.nl/malariavaccin
More at malaria
Related news items
Large AI project receives over €95 million for ten years of public-private research23 September 2021
The Dutch Research Council (NWO) is to fund two consortia for a period of ten years. Radboudumc participates in the ROBUST consortium, which consists of 17 AI labs, eight of which are dedicated to healthcare. Radboudumc leads five of these eight labs.read more
Reading ADP-ribosylation signaling using chemical biology and interaction proteomics published in Molecular Cell22 September 2021
Kasia Kliza and Michiel Vermeulen worked on a project to synthesize biotinylated ADPr-based probes that can identify ADPr readers and determine their specificity for mono- and polyADPr. They published this in Molecular Cell.read more
Systematic analysis of short tandem repeats in 38,095 exomes provides an additional diagnostic yield22 September 2021
Christian Gilissen and colleagues published in Genetics in Medicine about their work guiding the application of short tandem repeat analysis in clinical exome sequencing.read more
New start-up Patholyt will bring AI research into pathology diagnostics21 September 2021
Patholyt is on a mission to accelerate the adoption of artificial intelligence in pathology diagnostics and improve the chances of cancer patients worldwide. Patholyt is a spin-off from Radboudumc, a frontrunner in computational pathology research.read more